

Overview & Orthotic Management of Charcot Marie Tooth

David B. Misener, B.Sc.(H.K.), CPO, MBA,
CMTA Advisory Board Member
Clinical Prosthetics & Orthotics, LLC, Albany NY

Fred Rayner, B.Sc.(H.K.), C.O.(c),
C.Ped.(c)

Applied Biomechanics
214 Speedvale Ave. W., Unit 7
GUELPH, ON, N1H 1C4

Purpose of this Presentation

- Description of CMT
- Some History
- Understand the disease process
 - Pathophysiology
 - Pathomechanics
 - Critical insight into best orthotic designs
- Patient Evaluation
- Orthotic Management Options

Charcot Marie Tooth Disease

Aka:

- Peroneal Muscular Atrophy
- HMSN; Hereditary Motor Sensory Neuropathy
- Charcot-Marie-Tooth-Hoffman
- Tooth's Motor sensory neuropathy
- Description:
A progressive inherited neuropathy that is characterized by motor and sensory loss, predominantly in the feet and legs but also in the hands and arms.

This condition is one of the most common inherited neurological disorders, with 1 in 2,500 affected.

History

1886

2 papers were submitted in similar timeframe



Jean-Martin **Charcot**

61 y/o



Pierre **Marie**

33 y/o



Howard Henry **Tooth**
Cambridge Thesis:
"The Peroneal type of
Progressive Muscular Atrophy"

29 y/o

- **CMT1A** is an autosomal dominant disease resulting from a duplication of the gene on chromosome 17 that carries the instructions for producing the peripheral myelin protein-22 (PMP-22). The PMP-22 protein is a critical component of the myelin sheath.
- HMSN I, characterized by severely reduced motor nerve conduction velocities (NCV) (less than 38m/s) and segmental demyelination and remyelination with onion bulb formations on nerve biopsy *Demyelinating disease process*.
- **CMT2** CMT2A mapping to chromosome 1p36.2, results from abnormalities in the axon of the peripheral nerve cell rather than the myelin sheath.
- HMSN II, are characterized by normal or mildly reduced NCVs and chronic axonal degeneration and regeneration on nerve biopsy *Axonal Degeneration disease process*.
- **CMT2A1** Distal hereditary motor neuropathy (dHMN) is a spinal type of CMT characterized by exclusive motor involvement and sparing of sensory nerves (CMT) disease-2A1 results from mutation in the KIF1B gene ([605995](#)) on chromosome 1p36.2
- CMT2B ([600882](#)), CMT2B1 ([605588](#)), CMT2B2 ([605589](#)), CMT2C ([606071](#)), CMT2D ([601472](#)), CMT2E ([607684](#)), CMT2F ([606595](#)), CMT2G ([608591](#)), CMT2H ([607731](#)), CMT2I ([607677](#)), CMT2J ([607736](#)), CMT2K ([607831](#)), and CMT2L ([608673](#)).
- **CMT3 or Dejerine-Sottas disease** is a severe *demyelinating neuropathy* that begins in infancy. Infants have severe muscle atrophy, weakness, and sensory problems. This rare disorder can be caused by a specific point mutation in the P0 gene or a point mutation in the PMP-22 gene
- **CMTX** is an X-linked dominant disease and is caused by a point mutation in the connexin-32 gene on the X chromosome.
- (CMTX1) is X-linked dominant or X-linked intermediate; heterozygous females are more mildly affected than are hemizygous males. Ionasescu et al. (1991) presented data suggesting the existence of 2 separate loci for X-linked recessive disorders mapping to other sites:
- CMTX2 at chromosome Xp22.2 ([302801](#)) and CMTX3 at chromosome Xq26 ([302802](#))CMTX4. which maps to chromosome Xq24-q26, Cowchock syndrome ([310490](#)). CMTX5 at chromosome Xq21-q24 ([311070](#)).
 - Males who inherit one mutated gene from their mothers show *moderate to severe* symptoms of the disease beginning in late childhood or adolescence (the Y chromosome that males inherit from their fathers does not have the connexin-32 gene).
 - Females who inherit one mutated gene from one parent and one normal gene from the other parent may develop *mild* symptoms in adolescence or later or may not develop symptoms of the disease at all.

CMT >50 types.

CMT & HMSN: Demyelinating

Dominant

- [CMT 1A](#): PMP-22; 17p11
- [CMT 1B](#): P₀ protein; 1q22
- [CMT 1C](#): LITAF; 16p13
- [CMT 1D](#): EGR2; 10q21
- [CMT 1E](#): P₀ protein; 1q22
- [CMT 1F](#): NEFL; 8p21
- [HNPP](#): PMP-22 deletion; 17p11
- [HMSN 3](#) (Dejerine-Sottas)
- [CMT 2A1](#): KIF1B; 1p36

Recessive

- [CMT 4A](#): GDAP1; 8q21
- [CMT 4B](#): MTMR2; 11q23
- [CMT 4B2](#): SBF2; 11p15
- [CMT 4C](#): SH3TC2 (KIAA1985); 5q32
- [CMT 4D \(Lom\)](#): NDRG1; 8q24
- [CMT 4E](#): EGR2; 10q21
- [CMT 4F](#): Periaxin; 19q13
- [HMSN-Russe](#) (4G): HK1; 10q22
- [CMT 4H](#): FGD4; 12q12
- [CMT 4J](#): FIG4; 6q21
- [HMSN 3](#) (Dejerine-Sottas)

P₀; [PMP-22](#); [EGR2](#); [Periaxin](#)

[HMSN + Juvenile glaucoma](#)

[Cataracts \(CCFDN\)](#): CTDP1; 18qter

[Cockayne's](#): 5

[Congenital hypomyelinating](#)

P₀, PMP-22 & EGR-2

[Farber lipogranulomatosis](#): ASAH; 8p22

[CDG1a](#): PMM2; 16p13

[Krabbe](#): GALC; 14q31

[MLD](#): ARSA; 22q13

[PMP-22 point mutations](#)

Refsum's disease

[Childhood](#): PHYH; 10pter-p11.2

[Adolescent-Adult](#): PEX7; 6q22

[Infant](#): PEX1; 7q21

[Refsum-like](#): 20p11

[HMSN + CNS](#): Heterogeneous

[CMT 2A2](#): MFN2; 1p36

[CMT 2B](#): RAB7; 3q13-q22

[CMT 2C](#): 12q23-q24

[CMT 2D](#): GARS; 7p15

[CMT 2E](#): Neurofilament light chain; 8p21

[CMT 2F/ Distal HMN](#): HSPB1; 7q11-q21

[CMT 2G](#): 12q12

[CMT 2I](#): P₀; 1q22

[CMT 2J](#): P₀; 1q22

[CMT 2K](#): GDAP1; 8q21

[CMT 2L](#): HSPB8; 12q24

[HMSN-Proximal](#): 3q13

[CMT 2 + Cataracts](#): DNM2; 19p12

[HMSN 5 + Pyramidal signs](#): MFN2; 1p36

[HMSN + Optic atrophy](#)

[HMSN + Deafness](#)

P₀

[Connexin-31 \(GJB3\)](#)

[Eye ± Ear dysfunction](#)

[HMSN 6 + Visual loss](#): MFN2; 1p36

[HMSN + Ulcero-mutilation](#)

[HSN I](#)

[HSMN + Ataxia](#): IFRD1; 7q22

[HMN 5B](#): BSCL2; 11q13

Recessive

[AR-CMT2A](#): Lamin A/C; 1q21

[AR-CMT2B](#): MED25; 19q13.3

[AR-CMT + Pyramidal signs](#) (CMT 2H): 8q21.3

[AR-CMT + Hoarseness](#) (CMT 2K): GDAP1; 8q21

[AR-CMT, Severe & Early onset](#): NEFL; 8p21

[AR-CMT/Distal HMN](#): HSPB1; 7q11-q21

[Acrodystrophy](#)

[Andermann](#) (Corpus callosum Δ): KCC3; 15q13

[Ataxia with neuropathy](#): TDP1; 14q31

[Giant axonal](#): Gigaxonin; 16q24

[HMSN + Optic neuropathy ± Deafness](#)

[Infantile axonal + Respiratory failure](#)

[Lethal Neonatal](#)

[Neuroaxonal dystrophy](#)

[Ouvrier](#): Early childhood onset

Syndromes

[Childhood onset HMSN](#)

[CNS + HMSN](#)

[Deafness + HMSN](#)

Demyelination Disorders: [CMT 1, III \(Dejerine-Sottas\)](#), [4, HNPP](#), [Neuropathy with focally folded myelin sheaths](#), [Congenital hypomyelinating neuropathy](#)

Axonal: CMT type [II](#); [AR-CMT2](#); [HMSN 5](#); [HMSN 6](#)

Genes producing either demyelinating or axonal neuropathies Connexin-32 ([CMT-X](#))

X-linked

[Connexin-32](#) (Females):

Xq13

[2](#): Xp22.2

[3](#): Xq26

[4](#) (Cowchock): Xq24

[5](#): PRPS1; Xq22

[Sensory PN + Deafness](#):

Xq23

CMT + Intermediate NCV

Dominant

[CMT DIA](#): 10q24

[CMT DIB](#): DNM2; 19p12

[CMT DIC](#): tyrosyl-tRNA synthetase; 1p34

[CMT DI3](#): P₀; 1q22

[CMT-X \(Semi-dominant\)](#)

[CMT 2E](#): Neurofilament light chain; 8p21

Recessive

[CMT RIA](#): GDAP1; 8q21.1

How many of you know
specifically what type of
CMT you or your family
have?

Centre of Excellence

**Rochester - Closest
Iowa – Dr. Micheal Shy**

**EMG Studies
Bloodwork**

Patient complaints/presentation

- ❖ General foot weakness (foot drop, foot slap, weak push off)
- ❖ Unsteady gait (poor balance)
- ❖ Decreased proprioception: (where you are in space)
- ❖ Chronic lateral ankle sprains
- Glove and stocking hypoesthesia
 - “numbness”
- Atrophy of hand muscles
 - “Hand weakness, dropping things”
 - Thumb opposition
- Atrophy of distal leg muscles
- Claw toes
- Painful calluses
 - Base and head of 5th metatarsal
 - 1st and 5th met heads



- Does not affect longevity
- Primarily affects pts below elbows and knees
- Can predict severity (maybe)
- Managed well

Pathophysiology of CMT



Lower Extremity Insight Into orthotic management

- A specific **sequence** of muscle loss results in muscle imbalances which over time develops into the classic CMT deformities of :
 - Intrinsic minus toes
 - Plantar flexed 1st ray
 - Anterior cavus foot
 - Forefoot adduction at the mid tarsal joint
 - Inverted rear foot with lateral ankle instability
 - External rotation of the ankle and knee axes relative to the line of progression



Reason to foot shape: Actual sequence of muscle loss

- Intrinsics are first to go leaving extrinsic long toe flexors unopposed to create claw toes
- Peroneus longus out lasts its antagonist anterior tibialis with resultant plantar flexion of the first ray
- A rigidly plantar flexed 1st ray is almost impossible to stretch out and weight bearing imparts an inversion twist to the rear foot creating the “tripod effect”.
- Posterior tibialis out lasts its antagonist the peroneus brevis with unopposed forefoot adduction.
- Long extrinsic toe flexors out last extensors creating anterior cavus





Pes Cavus!



Classic characteristics associated with CMT




Classic CMT
from behind

Classic CMT hand



Tripod Effect


In static weight bearing, a rigid plantar flexed 1st ray imparts an inversion twist to the hind foot with resultant calcaneal varus



Lateral Block Test



Path of Pressure




- Normal Human Locomotion
- COG travels through a 2 inch corridor for maximum energy efficiency
- Normal Biomechanical Gait

Quality of the base



- An abducted or adducted forefoot will have an abnormal path of pressure
- Here as the COG passes over the base it will track lateral and off the base of the 5th metatarsal



Path of pressure....evidence



Evaluation

- History
 - Occupation, present activities, desired activities.
 - Complaints (what is hard to do?, what limits you?)
 - Weakness, instability, balance, reduced activity levels
 - Pathomechanical Assessment
 - Sensory Testing
 - Range of Motion
 - Manual Muscle Test
 - Gait Deviations
 - Balance
 - Cadence (gait)
- Ask, Explain, Discuss, Agree
 - Get some specifics on you want
 - may not have even thought about options
 - Describe orthotic options
 - Agree on a treatment plan

Goals: what can we achieve?

- Traditional orthotic goals:

- Prevent deformity
- Support and align skeletal structures
- Limit or enhance motion about a specific joint
-Balance

Treatment Options

Which Design is Right ?


- Determine Patient Goals
- Consider level of gadget tolerance.
- device is like a tool



BALANCE



- Simple physics of balance
- the COG must lie over the base of support



Prevention!!!!



- Simple FO's/SMO's
- Post to prevent lateral ankle instability
- Fore-foot varus post
- ST pad and 1st MP trap, and with weight bearing, prevent shortening of LA
- Stretching exercises to prevent tight achilles tendon, hamstrings

Accommodative/corrective FO's for fixed deformities

Forefoot valgus post for rigid plantar flexed 1st ray



Designs to prevent or slow the characteristics

- Inhibit lateral ankle instability with rear foot or fore foot posting
- Prevent forefoot adduction at mid-tarsal joint
- Prevent shortening of longitudinal arch:
 - trap 1st MP with intrinsic post
 - trap calcaneus with ST pad



Off the Shelf Carbon AFO's



Ground Reaction and dorsiflexion assist



Custom Energy Storing



Align Skeletal Segments Derotation



- ERD External Rotary Deformity
- Forefoot adduction at midtarsal joint
- Anterior cavus foot
- ER of ankle and knee axes relative to LOP
- COG not over base of support

- Extended medial foot plate
- Lateral mid tarsal slot strap
- Lateral sub talar slot strap
- Lateral calcaneal base modification
- ST pad and intrinsic FF valgus post
- Dorsi assist ankle joints
- Extended medial proximal trim







Silicone AFO's



Questions???



Thank you very much!!

..... and thanks to Ken Cornell, CO & Sean McKale, CO for some of the presentation content.